{"title":"玻璃体视网膜仪器的更新","authors":"Gerardo González-Saldivar, D. Chow","doi":"10.17925/USOR.2018.11.2.98","DOIUrl":null,"url":null,"abstract":"Disclosures: Gerardo González-Saldivar has nothing to declare in relation to this article. David R Chow declares the following financial interests or relationships: consultant/advisor for Alcon Laboratories, Inc., Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA and Katalyst; lecture fees for DORC International USA, OptoVue and Allergan; and equity ownership/stock options in public or privately traded firms, excluding mutual funds from Katalyst and Synergetics, Inc.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"98"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Update in Vitreoretinal Instrumentation\",\"authors\":\"Gerardo González-Saldivar, D. Chow\",\"doi\":\"10.17925/USOR.2018.11.2.98\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Disclosures: Gerardo González-Saldivar has nothing to declare in relation to this article. David R Chow declares the following financial interests or relationships: consultant/advisor for Alcon Laboratories, Inc., Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA and Katalyst; lecture fees for DORC International USA, OptoVue and Allergan; and equity ownership/stock options in public or privately traded firms, excluding mutual funds from Katalyst and Synergetics, Inc.\",\"PeriodicalId\":90077,\"journal\":{\"name\":\"US ophthalmic review\",\"volume\":\"11 1\",\"pages\":\"98\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"US ophthalmic review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/USOR.2018.11.2.98\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"US ophthalmic review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/USOR.2018.11.2.98","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
摘要
披露:Gerardo González-Saldivar没有任何与本文相关的声明。David R Chow声明以下财务利益或关系:Alcon Laboratories, Inc.， Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA和catalyst的顾问/顾问;DORC International USA、OptoVue、Allergan讲座费用;上市或私人交易公司的股权/股票期权，不包括来自catalyst and synergtics, Inc.的共同基金。
Disclosures: Gerardo González-Saldivar has nothing to declare in relation to this article. David R Chow declares the following financial interests or relationships: consultant/advisor for Alcon Laboratories, Inc., Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA and Katalyst; lecture fees for DORC International USA, OptoVue and Allergan; and equity ownership/stock options in public or privately traded firms, excluding mutual funds from Katalyst and Synergetics, Inc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
